Lanean...
The development of a recombinant hepatitis E vaccine HEV 239
Hepatitis E virus (HEV) infection is one of the main causes of acute hepatitis worldwide. A recombinant hepatitis E vaccine, HEV 239, has been licensed in China for immunizing adults of 16 y old and above. The vaccine antigen contains pORF2 aa 368 - 606 of the HEV genotype 1 expressed in E. coli. Th...
Gorde:
| Argitaratua izan da: | Hum Vaccin Immunother |
|---|---|
| Egile Nagusiak: | , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Taylor & Francis
2015
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4514148/ https://ncbi.nlm.nih.gov/pubmed/25714510 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2015.1008870 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|